CD-ROM and MONOGRAPH:
Douglas Mapel, MD, MPH
Lovelace Clinic Foundation
Albuquerque, New Mexico
ROUNDTABLE CONTRIBUTORS (MONOGRAPH):
Barry Make, MD
Professor of Medicine
Division of Pulmonary Sciences and
Critical Care Medicine
University of Colorado School of Medicine
Director, Emphysema Center, Pulmonary
Rehabilitation, and Respiratory Care Department
National Jewish Medical and Research Center
Frank Sciurba, MD
Associate Professor of Medicine
Director, Emphysema Research Center
Division of Pulmonary and Critical Care Medicine
University of Pittsburgh
Program CME Advisor:
Stanley A. Golanty, MD
The Institute for Medical Studies
Laguna Niguel, California
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the United States. Predominantly, but not entirely, a consequence of cigarette smoking, COPD remains a challenging disease to treat. Part of this challenge stems from inadequate consideration of the role of inflammation in disease symptomatology, progression, and exacerbation. A more throrough understanding of the different underlying inflammatory processes involved with COPD and its exacerbations will allow the health care practitioner to make a substantial improvement in the quality of life of his or her patients with COPD. There is no cure for COPD, but there are a variety of treatment options for its symptoms than can make a dramatic impact in the life of the COPD patient.
. Target Audience
Physicians and Physician Assistants interested in the management of COPD.
Upon completion of this educational activity, the participant should be able to:
Recognize the impact of COPD exacerbation on patient prognosis
Discuss the importance of population-based studies that have found a survival benefit among those patients with COPD using inhaled corticosteroids
Contrast newer and older models of COPD pathogenesis
Review the evidence for and against the use of inhaled corticosteroids in COPD
Douglas Mapel, MD, MPH discloses that he has received research grants from GlaxoSmithKline, Pfizer Inc, and Pharmacia & Upjohn, Inc. He will also be discussing off-label, unapproved and/or investigational uses of medications in this program.
Barry Make, MD discloses that he has received research grants or support from Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Sepracor, Inc. He has also received consulting fees from and is on the Speaker’s Bureau for Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline and Novartis Pharmaceuticals Corporation. He will also be discussing off-label, unapproved and/or investigational uses of medications in this program.
Frank Sciurba, MD discloses that he has received research grants, consultant fees and speaker’s fees from GlaxoSmithKline. He has received research grants and speaker’s fees from Boehringer-Ingelheim Pharmaceuticals, Inc. He has received research grants from Emphasys Medical, Inc., Abgenix Inc., and Otsuka America Pharma Inc. He is a consultant for Pfizer Inc, Roche Pharmaceuticals, AstraZeneca, and Amgen, Inc. He will also be discussing off-label, unapproved and/or investigational uses of medications in this program.
Stanley A. Golanty, MD has nothing to disclose.
Inhaled corticosteroids do not carry an FDA indication for COPD.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of
The Institute for Medical Studies and Medical Communications Media. The Institute for Medical Studies is accredited by the ACCME to provide continuing medical education for physicians.
The Institute for Medical Studies designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he or she actually spent in the activity.
The release date of this activity is April, 2003. Credit is valid through December 31, 2005. No credit will be given after this date.
AAPA accepts Category I CME credit for the PRA from organizations accredited by ACCME. All programs on cmecorner.com which carry ACCME Category I CME credit are acceptable towards the PA Category I (Preapproved) CME requirement.
Nurse Practitioners may be eligible to receive credit for completing AMA Category 1 activities from organizations accredited by the ACCME. If your state accepts AMA Category 1 credit, you are eligible to receive credit for this program.
PAs and NPs requesting credit should check the “Physician” box on the post-test.
Commercial Support Statements
Supported by an unrestricted educational grant from GlaxoSmithKline.
Click on the "Start program" icon.
The next screen will permit you to check for or download the Flash player required to run this program. You will also find buttons which will permit you to start the program presentation, access other program elements, and take the post-test.
Clicking on "start the program" on this screen will begin the program presentation which will take approximately 1 hour to complete.
You must be registered with cmecorner.com in order to complete the post-test. When you click on the post-test button you will be brought to a screen which will confirm your registration status and provide an opportunity to register if you haven't done so previously.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME or CE certificate.
© 2003, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions and ideas expressed in this publication and in the accompanying CD-ROM are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the Institute for Medical Studies, AKH Consultant, or GlaxoSmithKline. Any medication, diagnostic procedures or treatments discussed by the program faculty should not be utilized by clinicians or other health care professionals without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendation of other authorities.